ReviewHead and neck pathology2023
Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations.
Review in Head and neck pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Immunohistochemical characterization of the tumor immune microenvironment in laryngeal premalignancy: insights into early immune alterations in carcinogenesis.Virchows Archiv : an international journal of pathology · 2026Article
- Digital Pathology in Head and Neck Squamous Cell Carcinoma: Translational Advances and Clinical Integration for Pathologists, Oncologists, and Surgeons.Head and neck pathology · 2026Review
- Mechanistic investigation of artesunate against head and neck squamous cell carcinoma through network pharmacology and experimental validation.Discover oncology · 2026Article
- Molecular Mechanisms in Oral Squamous Cell Carcinoma: Integrative Roles of Cancer-Associated Fibroblasts, Immune Microenvironment, and Precision Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Precision immuno-oncology in oral cancer: latest trends in biomarkers, novel drug development and nanoparticle-based therapeutic platforms.Frontiers in cell and developmental biology · 2026Review
- The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application.ImmunoTargets and therapy · 2026Review
- Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition.Clinical and translational medicine · 2025Article
- Single-cell analysis of tumor microenvironment immune homeostasis and identification of prognostic biomarkers in head and neck squamous cell carcinoma.Translational cancer research · 2025Article
- Review
- LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.Future oncology (London, England) · 2025Article
- Integrated peripheral blood multi-omics profiling identifies immune signatures predictive of neoadjuvant PD-1 blockade efficacy in head and neck squamous cell carcinoma.Journal of translational medicine · 2025Article
- Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer.Cell reports. Medicine · 2025Article
- Immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma: PD-L1 and beyond.Pathologica · 2025Review
- Releasing the brakes: the role of immune checkpoint inhibitors in laryngeal cancer.Exploration of targeted anti-tumor therapy · 2025Review
- Comparison of PD-L1 expression in head and neck squamous cell carcinoma among preoperative biopsy, surgical resection and metastatic lymph node.Frontiers in oncology · 2025Article
- CMTM6 status predicts survival in head and neck squamous cell carcinoma and correlates with PD-L1 expression.Discover oncology · 2024Article
- Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.Head and neck pathology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Immune checkpoint inhibitors have improved the outcome of patients diagnosed with inoperable recurrent or metastatic head and neck squamous cell carcinoma. However, as only a subset of head and neck cancer patients benefit from this treatment, biomarkers predicting treatment response help guide physicians in their clinical decision-making. PD-L1 expression assessed by immunohistochemistry is the single most clinically relevant biomarker predicting response to PD-1-blocking antibodies. Here, we discuss in which clinical context assessment of PD-L1 expression is instrumental for the choice of therapy, how pathologists score it, and how it affects the approval of anti-PD-1 antibodies. Furthermore, we discuss the heterogeneity of PD-L1 expression and review technical aspects of determining this prominent biomarker-knowledge that might influence clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.